Monopar Therapeutics Inc.
1000 Skokie Blvd., Suite 350
Wilmette, Illinois 60091
October 2, 2019
VIA EDGAR
US Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Re:
Monopar Therapeutics Inc.
Registration Statement on Form S-1
File No. 333-233303
Ladies and Gentlemen:
In prior correspondence, dated September 30, 2019, Monopar Therapeutics Inc. (the “Company”) requested that the above-referenced Registration Statement be declared effective at 4 p.m., Eastern time, on October 2, 2019 (the “Acceleration Request”). The Acceleration Request is hereby withdrawn by the Company.
Please contact John Harrington of Baker & Hostetler LLP at (216) 861-6697 with any questions regarding the foregoing.
Very truly yours,
| | Monopar Therapeutics Inc. | |
| | | | |
| By: | /s/ Chandler D. Robinson | |
| | | Name: Chandler D. Robinson | |
| | | Title: Chief Executive Officer | |
